Gilead Prices $3 Billion of Senior Unsecured Notes
Gilead Sciences priced a $3 billion offering of senior unsecured notes across four tranches maturing between 2028 and 2034. The weighted average interest rates range from 4.25% to 4.90%, reflecting current market conditions for investment-grade biopharma debt.
Key figures
- Deal Value Usd
- 3000000000
- Note 2028 rate
- 4.250%
- Note 2029 rate
- 4.400%
- Note 2031 rate
- 4.600%
- Note 2034 rate
- 4.900%
- Note 2028 amount
- 500000000
- Note 2029 amount
- 1000000000
- Note 2031 amount
- 1000000000
- Note 2034 amount
- 500000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.